Stay updated with breaking news from Multicenter Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Eight Presentations on Yescarta and TecartusAdvance Kite's Cell Therapy Leadership - - New Data Highlight Magrolimab's Potential to Alter the Tumor Microenvironment - Gilead Sciences, Inc. (Nasdaq:
– Eight Presentations on Yescarta® and Tecartus® Advance Kite’s Cell Therapy Leadership – – New Data Highlight Magrolimab’s Potential to Alter the Tumor... | June 1, 2023
/PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that the updated results of Phase Ib study of its CSF-1R...
A class of drugs used for their ability to stop tumor cells from dividing is now under study for their potential to reduce the pain and damage caused by sickle cell disease, investigators report.
Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 GRAPHITE study presented at the 2023 Tandem Meetings, demonstrating vedolizumab achieved a statistically significant and clinically meaningful improvement in lower gastrointestinal (GI) aGvHD-free survival by Day 180 after allo-HSCT with no relevant differences in safety profile versus placebo.1